Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension

Chest
Joanna Pepke-ZabaMartin C J Brown

Abstract

Sildenafil inhibits phosphodiesterase-5, enhancing cyclic guanosine monophosphate- mediated relaxation of pulmonary vasculature and is effective in treating patients with pulmonary arterial hypertension (PAH). Patients with PAH (n = 278) received oral sildenafil (20, 40, or 80 mg three times daily) in a 12-week, double-blind, placebo-controlled study and an open-label extension. Health-related quality of life (HRQoL) was recorded by patients using the Medical Outcomes Study 36-item short form (SF-36) and EuroQol 5D (EQ-5D) questionnaires at baseline and after 12 and 24 weeks of therapy. Data are presented for patients who received sildenafil for up to 24 weeks. Sildenafil-treated patients, compared with placebo-treated patients, exhibited significant improvement in exercise capacity at week 12 (p < 0.001). Increases from baseline to week 12 were observed in all SF-36 domains for sildenafil-treated patients, with statistically significant improvements, compared with placebo-treated control subjects, in physical functioning (p < 0.001), general health (p < 0.001), and vitality (p < 0.05). Statistically significant improvements were also observed for the EQ-5D current health status (p < 0.01) and utility index (p < 0.01). These be...Continue Reading

References

May 1, 1996·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·L J OkamotoD J Kellerman
Apr 5, 2000·PharmacoEconomics·S J CoonsR D Hays
May 26, 2001·BMJ : British Medical Journal·I J Higginson, A J Carr
May 28, 2003·Journal of Clinical Epidemiology·Jacek A Kopec, Kevin D Willison
Jun 25, 2003·Journal of the American College of Cardiology·Robyn J BarstUNKNOWN Beraprost Study Group
Jun 15, 2004·Journal of the American College of Cardiology·Alfred P Fishman
Aug 20, 2004·American Journal of Respiratory and Critical Care Medicine·Olivier SitbonGérald Simonneau
Oct 2, 2004·The New England Journal of Medicine·Marc HumbertGérald Simonneau
Mar 12, 2005·Heart & Lung : the Journal of Critical Care·Maureen P FlatteryJeanne Salyer
Nov 18, 2005·The New England Journal of Medicine·Nazzareno GalièUNKNOWN Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group
Jan 18, 2006·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·S P McKennaJ Pepke-Zaba
May 19, 2006·The European Respiratory Journal·E CenedeseM Fischler

❮ Previous
Next ❯

Citations

Jan 21, 2011·American Journal of Therapeutics·Ali Salehi
Apr 24, 2010·Journal of Veterinary Internal Medicine·A J BrownM M Sleeper
Jun 23, 2012·American Journal of Respiratory and Critical Care Medicine·Stephen C MathaiRobert A Wise
Jul 13, 2013·BMC Pulmonary Medicine·James TwissEli Gabbay
Dec 31, 2010·Vascular Health and Risk Management·Samuel T Nadler, Jeffrey D Edelman
May 19, 2010·Vascular Health and Risk Management·Jeremy A FalkErnst R Schwarz
Aug 21, 2015·Expert Review of Respiratory Medicine·Nicholas S HillIoana Preston
Jan 26, 2010·Expert Opinion on Emerging Drugs·Reda E Girgis
Aug 19, 2009·Current Medical Research and Opinion·Joanna Pepke-ZabaMallik Angalakuditi
Aug 15, 2014·Chest·Stephen C MathaiRobert A Wise
Oct 23, 2015·Annals of the American Thoracic Society·Stephen C MathaiPaul M Hassoun
Mar 10, 2012·Free Radical Biology & Medicine·Diana M TabimaMark T Gladwin
Dec 3, 2014·European Respiratory Review : an Official Journal of the European Respiratory Society·Luke S HowardSanjay Mehta
Dec 14, 2018·The European Respiratory Journal·Michael D McGoonBrad A Wong
Dec 2, 2015·European Respiratory Review : an Official Journal of the European Respiratory Society·Marion Delcroix, Luke Howard
Dec 21, 2018·European Respiratory Review : an Official Journal of the European Respiratory Society·Ghaleb KhirfanSandeep Sahay
May 16, 2018·Molecular and Cellular Biochemistry·Palak GalhotraSubir Kumar Maulik
Oct 11, 2019·Obstetrics and Gynecology·Stephanie R Martin, Alexandra Edwards
Dec 7, 2013·Endocrine Reviews·Monalisa F AzevedoConstantine A Stratakis
Apr 1, 2020·Frontiers in Pharmacology·Seyed Vahid JasemiJavier Echeverría
Feb 9, 2008·Drugs·Katherine F Croom, Monique P Curran
May 28, 2009·Circulation·Nazzareno GalièUNKNOWN Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group
Dec 6, 2019·Journal of Pain and Symptom Management·David ChristiansenKirsten Wentlandt
Oct 22, 2020·Annals of the American Thoracic Society·Jeff MinUNKNOWN PHAR Investigators
Oct 16, 2021·Cardiovascular Drugs and Therapy·Sumon RoyIon S Jovin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.